TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04561661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous pinning
Description: Closed reduction, percutaneous pinning and plaster

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Closed reduction, custom made orthosis and early mobilization
Study: NCT05917327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-volume continuous veno-venous haemodialysis
Description: MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
Study: NCT05180162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-2286
Description: A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-2286
Description: A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-2286
Description: A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging will begin 50-100 minutes after injection and last about 45 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging will begin 50-100 minutes after injection and last about 45 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging will begin 50-100 minutes after injection and last about 45 minutes.
Study: NCT06473831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet System, DI Biofragmentable
Description: Anastomoses achieved by magnetic compression.
Study: NCT05458947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed wound irrigation (PWI)
Description: necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrical stimulation (ES)
Description: high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrical stimulation (ES) and pulsed wound irrigation (PWI)
Description: necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
Study: NCT06489314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAD (Learn, Engage, Act, Dedicate)
Description: LEAD is a 5-session behavioral activation (BA) intervention delivered by peer-father counselors. LEAD also incorporates motivational interviewing (MI) and masculinity discussion strategies. This is a task-shifted intervention meaning mental health service tasks are delegated to non-specialist providers, in this case peer-fathers, as opposed to a specialized workforce (e.g., psychiatrists, psychologists).
Study: NCT06013449

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field (PEMF) Device
Description: Pulsed Electromagnetic Field (PEMF) Device BEMER Device consist of a total body mat (B. BODY) plus a targeted pelvic mat (B.PAD), and a Control Unit which powers the device and logs usage. Both B.BODY and B.PAD must be plugged into the Control Unit simultaneously and activated individually. B. Body must be placed on a flat surface (i.e. bed, floor, reclining chair etc.) for best results.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed Electromagnetic Feild (PEMF) Device
Description: The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
Study: NCT06299449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free-hand socket shield
Description: Immediate Implant Placement Using Socket Shield Technique with autogenous whole tooth graft after immediate implantation using Socket Shield Technique, the palatal root portion and the decoronated crown will be converted to autogenous whole tooth graft and used for grafting the defect between the socket shield and the implant fixture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI/guided socket shield
Description: The patient specific guides will be placed at the pre-planned positions at the labial buccal mucosa.~using artificial intelligence the socket shield approach will be planned to keep the buccal shield and using surgical guide the shield will be preciesly prepared followed by guided implant placement and whole tooth grafting of the jumping gap
Study: NCT05010317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance based therapy
Description: This is a behavioral intervention that is aimed at building psychological flexibility among adolescents. It involves careful use of language, metaphors, experiential learning and mindfulness to develop skills that support values guided living. Participants learn to relate with their inner thoughts, feelings and urges in an open and elaborative way as conscious human beings and make choices that improve their lives even in the presence of such difficult experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Usual clinic based counselling offered as routine care to adolescents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Usual clinic based counselling offered as routine care to adolescents
Study: NCT06494592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants in the aerobic exercise intervention group will engage in a virtual aerobic exercise intervention three times a week for 12 weeks for a 30-minute session (5 minute warm up, 20 minutes of aerobic exercise, 5 minutes cooldown) and will receive information about the session prior to their appointment. Sessions have a goal of reaching at least 20 minutes of supervised exercise performed at 80% of the heart rate at symptom threshold.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Exercise
Description: Participants in the balance exercise intervention group will participate in a staff-led virtual session three times a week for 12 weeks for a 30-minute session and will receive information about the session prior to their appointment. This group will focus on improving balance, with some additional work on flexibility and strength.
Study: NCT05660668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transbond LR
Description: cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond LR will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transbond XT
Description: cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond XT will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
Study: NCT05807035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radvax
Description: Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant
Study: NCT04769674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Integration Intervention through the STAR Frame of Reference
Description: The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
Study: NCT05061147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: Drug: AZA AZA will be administered at 75 mg/m\^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.~Other Name: Azacitidine~Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.~Other Name: NA
Study: NCT06175208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques
Description: Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
Study: NCT04953143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiverPal Intervention
Description: Inpatient longitudinal palliative care intervention~- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period~LiverPal intervention domains include the following:~* Therapeutic relationship~* Symptom management~* Coping with illness~* Prognostic awareness and illness understanding~* Treatment decision-making~* End-of-life care
Study: NCT05075863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole as 5mg from day 3 to 7 of menstrual cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole as 5mg from day 3 to 7 of menstrual cycle
Study: NCT04062721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: Complete macroscopic ablation by RFA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In situ immunotherapy
Description: Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.
Study: NCT05399147

Intervention type: OTHER
Group type: OTHER
Intervention: fiberoptic intubation classic technique
Description: classic fiberoptic intubation

Intervention type: OTHER
Group type: OTHER
Intervention: fiberoptic intubation tube 1st technique
Description: tube 1st technique
Study: NCT04332926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: 4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: 4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: 4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: 4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: 4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
Study: NCT05079256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 595 nm Pulsed dye laser (Candela V-beam perfecta)
Description: 595 nm pulsed dye laser therapy. 2 treatments Fluence \~ 6 - 9 J/cm\^2 Pulse duration \~ 0.45 - 3.0 ms 33% overlap.
Study: NCT05125302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet
Study: NCT05392530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film coated tablets will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film coated tablets will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film coated tablets will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film coated tablets will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film coated tablets will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
Study: NCT06039137

Intervention type: DRUG
Intervention: Cetirizine
Description: Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine

Intervention type: DRUG
Intervention: Clemastine IV
Description: Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV
Study: NCT04912479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: connected watch
Description: connected watch that provide to patients with information on their sleep quality and their performed activities
Study: NCT06265337

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactate
Description: Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactate
Description: Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
Study: NCT04615078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETAPES Program
Description: The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~* A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~* An organizational solution relying on a nurse call center.
Study: NCT05462236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinodasertib
Description: MNK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinodasertib
Description: MNK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinodasertib
Description: MNK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Topoisomerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Topoisomerase inhibitor
Study: NCT04817176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program
Description: Experimental Arm: The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Nutrition Program
Description: Active Comparator Arm: 6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
Study: NCT03360019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activlink insole
Description: Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activlink insole
Description: Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.

Intervention type: OTHER
Group type: OTHER
Intervention: Activlink Phone Application
Description: Smartphone tool used for monitoring location
Study: NCT05355077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001 200mg Bid
Description: JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001 400mg Bid
Description: JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001 600mg Bid
Description: JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
Study: NCT06144203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete either a 30-minute bout of light-, moderate-, or high-intensity aerobic exercise at one of the visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete either a 30-minute bout of light-, moderate-, or high-intensity aerobic exercise at one of the visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete either a 30-minute bout of light-, moderate-, or high-intensity aerobic exercise at one of the visits.
Study: NCT04949282

Intervention type: DRUG
Intervention: Lutetium [177Lu] oxodotreotide/dotatate
Description: Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

Intervention type: DEVICE
Intervention: Lutetium [177Lu] oxodotreotide/dotatate
Description: Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Study: NCT04712864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LB1901
Description: LB1901 - an autologous CD4-targeted CAR-T immunotherapy
Study: NCT05680077

Intervention type: DIAGNOSTIC_TEST
Intervention: KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Description: Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Description: Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.
Study: NCT01243515

Intervention type: DEVICE
Intervention: Non-Invasive Central Venous Pressure monitor
Description: An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)

Intervention type: DEVICE
Intervention: Non-Invasive Central Venous Pressure monitor
Description: An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)

Intervention type: PROCEDURE
Intervention: Physical examination of jugular vein
Description: Physicians assess CVP using the jugular vein of the subject

Intervention type: PROCEDURE
Intervention: Physical examination of jugular vein
Description: Physicians assess CVP using the jugular vein of the subject
Study: NCT06484283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided meditation will be applied within the scope of the study. A guided meditation video prepared by a Yoga Alliance-certified researcher will be used for this intervention. Guided meditation aims to ensure being in the moment (here and now) with the help of breathing. Meditation practice will take participants 10 minutes.